Overview of Aquaflor*

Key Benefits:

• Aquaflor* (florfenicol) 50% Premix is an in-feed antibiotic premix with a broad spectrum of antimicrobial activity. Proven to be highly effective in the treatment of bacterial infections in a wide range of finfish species.
• Aquaflor* contains unique, broad-spectrum antibacterial florfenicol. This antibiotic has proven effectiveness against economically important fish pathogens, including multiple antibiotic resistant organisms.
• Aquaflor* has an excellent safety profile and may be used at any stage of production from Fry to market-weight fish.
• Aquaflor* is extremely palatable, which ensures rapid ingestion of the therapeutic dose for rapid onset of therapeutic activity and limits wasted feed.
• Fish treated with Aquaflor* may be harvested after a short withdrawal period following the end of treatment.
• Aquaflor* is available in convenient foil pouches and is easy to mix and administer in feed for Fry to market weight fish.

• Commercial Field Trials: Norway, Canada (245kb)
  Experimental models have been developed for some bacterial fish pathogens however there is still a paucity of knowledge on the routes of infection and pathogenesis of many fish pathogens. Natural bacterial disease outbreaks on farms represent an alternative testing arena although these are often a complicated and expensive means of testing efficacy. Further trials on farms with untreated controls may not be acceptable either ethically or economically and the usual requirement is that the test compound must be tested against products already established as effective against the disease. Dose rate determination and dose rate confirmation studies were conducted at several locations in Scotland and one in Norway. In the confirmation studies in salmon, the challenge bacteria were Aeromonas salmonicida and Vibrio salmonicida and florfenicol medicated feed was administered to supply the recommended dose rate of 10 mg/kg for 10 consecutive days. Commercial field trials were conducted in Norway and Canada against furunculosis. In Norway the efficacy of florfenicol was compared to that of other antibacterials administered in feed, specifically oxolinic acid, potentiated sulphonamide (trimethoprim & sulphadiazine) and flumequine. In the Canadian trials the efficacy of florfenicol was compared to erythromycin or unmedicated feed. Results from the five study sites in Norway and the three study sites in Canada showed that florfenicol medicated feed provided better sustained efficacy against furunculosis when compared to positive and negative controls.